Systematic Biology Basis of Constitution and Essence of Traditional Chinese Medicine Syndromes in Spleen Qi Deficiency of Chronic Atrophic Gastritis

2018 ◽  
Author(s):  
Guihua Tian ◽  
Feilong Zhang ◽  
Hongmei Li ◽  
Kuo Gao ◽  
Jinping Wang ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Atrophic Gastritis ◽  
Chronic Atrophic Gastritis ◽  
Systematic Biology

Mechanism of E Lian Granule Reversing Chronic Atrophic Gastritis With Intestinal Metaplasia Based on Integrated Pharmacology and GEO Gene Chip

2021 ◽  
Author(s):  
Sizhen Gu ◽  
Yan Xue ◽  
Shigui Xue ◽  
Yini Tang ◽  
Zhehao Hu ◽  
...  
Keyword(s):  
Molecular Docking ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Atrophic Gastritis ◽  
Intestinal Metaplasia ◽  
Precancerous Lesions ◽  
Chronic Atrophic Gastritis ◽  
Network Computing ◽  
Active Components ◽  
Gene Chips

Abstract Background: This study aimed to explore the main components and targets of E-Lian granule through which it reversed chronic atrophic gastritis with intestinal metaplasia, based on the traditional Chinese Medicine Integrated Pharmacology Network Computing Research Platform V2.0 (TCMIP V2.0) combined with GEO gene chips. It also aimed to construct various networks to predict and analyze the mechanism of E-Lian granule in treating gastric precancerous lesions. Methods: The effective traditional Chinese medicine components and targets of E-Lian granule prescription were obtained using TCMIP V2.0. The disease targets were collected using the TCMIP V2.0 platform and the verified gene chips in the GEO database, and the “drug components–targets” network, “compound–targets protein interaction network,” and “core compound targets–pathways network” were constructed using Cytoscape 3.6.1. The reliability of the predicted components and targets was verified using Pymol 1.7.2.1 and Autodock Vina 1.1.2 reverse molecular docking. Results: A total of 262 unique active components and 680 potential active targets of E-Lian granule were obtained. Moreover, 2247 unique disease targets of chronic atrophic gastritis with intestinal metaplasia were obtained by searching the “Disease/Symptom Target Database” combined with the GEO chip (GSE78523) and GeneCard database. Further, 178 complex targets and 38 complex core targets were obtained using Venn and Filter, respectively, such as ALB, TNF, PTGS2, RHOA, ESR1, HRAS, JUN, FOS, CASP3 and so forth. The GO and KEGG nrichment analyses showed that E-Lian granule reversed gastric precancerous lesions not only through the direct intervention of the cancer pathway, gastric cancer pathway, and epithelial signal transduction in Helicobacter pylori infection but also through PI3K/AKT, VEGF, MAPK, cAMP, cGMP, Th1/Th2,and other pathways. It also had a significant correlation with cholinergic, 5-hydroxytryptamine, dopaminergic, and other gastrointestinal hormone-related signals. Finally, the core target verified in the GSE78523 chip was successfully used to dock with the active components of E-Lian granules. The reliability of the prediction was also verified. Conclusions: The components and molecular mechanism of E-Lian granule in reversing chronic atrophic gastritis with intestinal metaplasia were predicted by integrated pharmacology, GEO chip, and reverse molecular docking, providing an important theoretical basis for further study of the effective substances and mechanism of E-Lian granule in treating chronic atrophic gastritis.

scholarly journals Efficacy and Safety of Elian Granules in Treating Chronic Atrophic Gastritis: Study Protocol For a Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

2021 ◽  
Author(s):  
Zhijian Gu ◽  
Jun Cong ◽  
Biao Gong ◽  
Rong Cen ◽  
Yongqi Chen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Atrophic Gastritis ◽  
Intestinal Metaplasia ◽  
Chronic Atrophic Gastritis ◽  
Efficacy And Safety ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background: Multifocal atrophic gastritis and intestinal metaplasia are considered to be important links of the gastric precancerous cascade. But, there is a lack of definite therapeutic drugs for them. Many studies have shown traditional Chinese medicine is effective and no serious side effects have been identified. However, the studies that have been carried out were not scientifically rigorous trials. Our aim is to design a high-quality trial for a Chinese patent medicine, Elian granules, to investigate the efficacy and safety of this drug in treating chronic atrophic gastritis patients with or without intestinal metaplasia.Methods: This is a phase Ⅱ, randomized, double-blind, placebo-controlled, multicenter clinical trial. A total of 240 participants will be assigned to treatment group or placebo control group with a 1:1 ratio. Then, the experimental drug or placebo will be taken with boiling water,2 small bags (24.2g) each time, twice times a day, half an hour after each meal for 24 weeks. The primary outcome is to observe gastric mucosal histological changes after 6 months in patients with atrophic gastritis with or without intestinal metaplasia based on OLGA/OLGIM. The secondary outcome included dyspepsia symptom score and quality of life scale.Discussion: This study is designed to evaluate the efficacy and safety of Elian granule in a randomized, double-blind, placebo-controlled, multicenter manner. This trial may not only provide evidence for a phase III clinical trial, but also a vision of an alternative option for chronic atrophic gastritis(CAG) treatment.Trial registration: The registration number, ChiMCTR2000003929, was assigned by the Registry Platform For Evidence Based Traditional Chinese Medicine on 13 September 2020.

LncRNA- and circRNA-associated competing endogenous RNA (ceRNA) networks in leukocytes in traditional Chinese medicine (TCM)-defined Pi-qi-deficiency syndrome and Pi-wei damp-heat syndrome resulting from chronic atrophic gastritis

2021 ◽  
Author(s):  
Leiming You ◽  
Wei Wang ◽  
Kunyu Li ◽  
Xiaopu Sang ◽  
Ting’an Li ◽  
...  
Keyword(s):  
Gene Regulation ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Atrophic Gastritis ◽  
Regulatory Networks ◽  
Chronic Atrophic Gastritis ◽  
Deficiency Syndrome ◽  
Competing Endogenous Rna ◽  
Relationship Networks ◽  
Heat Syndrome

Abstract Background To investigate lncRNA/circRNA-associated competing endogenous RNA (ceRNA)-gene regulation underlying leukocyte functions and characteristics, especially the potential ceRNA biomarkers, implicated in traditional Chinese medicine (TCM)-defined Pi-qi-deficiency syndrome (PQDS) and Pi-wei damp-heat syndrome (PDHS) resulting from chronic atrophic gastritis (CAG). Methods Based on RNA-sequencing approach, comparing with healthy control population, we identified the PDHS- or PQDS-specific lncRNAs/circRNAs in leukocytes, especially the Zheng (syndrome)-specific ceRNAs and their corresponding ceRNA regulatory networks, further decoding their potential functions and pathways. Results Despite being the TCM-defined Zhengs resulting from the same disease of CAG, the Zheng-specific lncRNAs/circRNAs in leukocytes were not same in PQDS and PDHS. There were the Zheng-specific lncRNA/circRNA-associated ceRNAs identified in the leukocytes, and their corresponding ceRNA regulatory networks were generated, including the ceRNA-gene binary relationship networks and the miRNA-centered ceRNA-miRNA-gene triple relationship networks. In the generated Zheng-specific ceRNA networks, the PQDS-specific ceRNA-governed genes in leukocytes, keeping more complex interactions with each other, were enriched in pathways related to MAPK signaling, receptor tyrosine kinases signaling as well as complement and coagulation cascades. Notably, the enriched pathways associated with adherens junction, focal adhesion, ECM-receptor interaction, ECM-organization and cell surface interactions, were implicated in cell-to-cell adhesion/junction and communication, probably contributing to the characteristics and functions of leukocytes. The PDHS-specific ceRNA-regulated genes, seemed to have no more interactions with each other, were enriched in the biological processes related to regulation of cell morphogenesis, neutrophil activation and degranulation, and lymphocyte mediated immunity such as B-cell receptor signaling, complement and coagulation cascades, and regulation of NK/T-cell mediated cytotoxicity. Importantly, the five exosome-encapsuled ceRNAs, containing ZFAS1 (NR_036658.2), AL353719.1 (ENST00000566847), LOH12CR2 (NR_024061.1) and two new lncRNAs (TCONS_00038035 and TCONS_00027600), particularly higher expression in the leukocytes in PQDS rather than PDHS, could be the potential ceRNA biomarkers for differentiation of the TCM-defined PQDS and PDHS among CAG patients. Conclusions These results may provide new insights into the characteristic and functional changes of leukocytes in the two TCM Zhengs, especially the Zheng-specific ceRNA-mediated gene regulation underlying leukocyte characteristics and functions, with potential leukocyte biomarkers for future application in integrative medicine.

scholarly journals The effect of the fortifying the spleen, clearing heat, activating blood method on chronic atrophic gastritis: a real-world study

2020 ◽  
Author(s):  
Zhihua Zheng ◽  
Yi Wen ◽  
Yanhua Yan ◽  
Zhiheng Xu ◽  
Kechao Nie ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Treatment Group ◽  
Atrophic Gastritis ◽  
Real World ◽  
Natural Science ◽  
Chronic Atrophic Gastritis ◽  
Secondary Outcome ◽  
Curative Effect ◽  
Research Project ◽  
Number Of Patients

AbstractIntroductionChronic atrophic gastritis (CAG) is a precancerous disease that is difficult to treat. Even after eradication of the Helicobacter pylori (HP) infection, complete resolution of the symptoms is difficult to achieve. The fortifying the spleen, clearing heat, activating blood method (FSCHABM) has an excellent curative effect in the treatment of CAG. A real-world study is particularly suitable for researching the treatment of CAG, but there are currently no reports on CAG trials. Our aim is to design a high-quality trial to investigate the efficacy and safety of FSCHABM in treating CAG patients.Methods and analysisThis protocol is designed as a real-world study for 10 years. A total of 5000 participants will be assigned to a FSCHABM treatment group or a non-FSCHABM treatment group at a 1:1 ratio at the first Affiliated Hospital of Guangzhou University of Chinese Medicine. Patients are given 1-2 courses of a 24-week-long treatment. The participants will be followed up for observation and measurement of the following indicators: the primary outcome is the histopathological indicator; the secondary outcome includes evaluation of gastric lesions, syndrome curative effect, evaluation of symptoms, evaluation of quality of life, evaluation of anxiety and depression, economic evaluation and other indicators. This is the first real-world study evaluating the therapeutic effect of FSCHABM in the treatment of CAG in clinical practice. This protocol can provide a reference for future multi-center, randomized, controlled trials.Strengths and limitations of this studyit is the first time to carry out TCM study related to CAG by using the real-world study. A large number of patients and a long-term study can effectively reflect the effect of TCM treatment and reduce the bias. The precise research protocol makes the whole research more accurate and reliable. The limitations of implementing this protocol are expending a lot of time, manpower and economic resources inevitably.Ethics and disseminationthis study was approved by Ethical committee of the first Affiliated Hospital of Guangzhou University of Chinese Medicine. Study findings will be shared with participants, healthcare providers, and policymakers through research reports, conference presentations, and the Internet. The results will also be disseminated through publication in peer reviewed journals.Trial registrationThe registration number, ChiCTR1900027177, was assigned by the Chinese Clinical Trial Registry on 3 November 2019.FundingThis work was supported by Guangdong natural science fund project, China (2019),No.2019A1515011145; Major research project of Guangzhou University of Chinese medicine, China (2019), No.A1-2606-19-110-007; The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” clinical research project, China (2019), No.2019IIT19; Guangdong natural science foundation (PhD) project, China (2017), No.2017A030310121; The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” innovation research team project, China (2017), No.2017TD05; The first affiliated hospital of Guangzhou University of Chinese medicine “innovation foster hospital” Youth scientific research talent training program, China (2015), No.2015QN09.

Sign in / Sign up

Export Citation Format

Share Document